<DOC>
	<DOCNO>NCT02304354</DOCNO>
	<brief_summary>Rituximab , anti CD-20 monoclonal antibody target B lymphocytes prescribe rheumatoid arthritis ( RA ) patient refractory TNF alpha antagonist . According previous study , 25 50 % patient insufficient absence response rituximab week 24 . In recent retrospective study , CD4+ T-lymphocytes depletion observe first course rituximab RA patient . The absolute CD4+ number week 12 37 % ( ±33 ) baseline value , lead &lt; 200 cells/µL 5 % patient . Interestingly absence CD4+ T-lymphocytes depletion observe clinical non-responders , suggest involvement T-lymphocytes mechanism action rituximab . So far prospective study support usefulness lymphocyte phenotyping , particular T-lymphocytes , monitor rituximab-treated RA patient .</brief_summary>
	<brief_title>Relationship Between T LYmphocytes Depletion Clinical Response RITUXimab Rheumatoid Arthritis ( LYRITUX )</brief_title>
	<detailed_description>Rituximab , anti CD-20 monoclonal antibody target B lymphocytes prescribe rheumatoid arthritis ( RA ) patient refractory TNF alpha antagonist . According previous study , ( Edwards , Szczepanski et al . 2004 ; Cohen , Emery et al . 2006 ; Emery , Fleischmann et al . 2006 ) 25 50 % patient insufficient absence response rituximab week 24 . In pathogenesis RA , B T lymphocytes tightly link APC fonction cytokine production B lymphocytes . At present , white blood cell count recommend routine every 3 month patient receive rituximab , since case neutropenia observe approximately 8 % patient lymphoma treatment . In RA patient , B lymphocytes count rituximab course do prevent opportunistic infection ( Pham , Fautrel et al . 2008 ) . In recent retrospective study , CD4+ T-lymphocytes depletion observe first course rituximab RA patient . The absolute CD4+ number week 12 37 % ( ±33 ) baseline value , lead &lt; 200 cells/µL 5 % patient . Interestingly absence CD4+ T-lymphocytes depletion observe clinical non-responders , suggest involvement T-lymphocytes mechanism action rituximab ( Mélet , Mulleman et al . 2013 ) . Moreover , case report RA patient develop opportunist infection conjunction CD4+ T-lymphocyte depletion publish ( Teichmann , Woenckhaus et al . 2008 ; Clifford , Ances et al . 2011 ) . So far prospective study support usefulness lymphocyte phenotyping , particular T-lymphocytes , monitor rituximab-treated RA patient .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>RA accord American College Rheumatology ( ACR ) criteria Treatment adalimumab accordance SPC Disease modify anti rheumatic drug ( DMARDs ) stable 4 week enrollment 16 week . Signed consent No anti TNFalpha failure contraindication Previous adalimumab treatment Contraindication adalimumab , methylprednisolone methotrexate ( use combination adalimumab ) methotrexatenaive patient Any hematologic disease affect lymphocyte ( particular lymphoma ) Any osteoarticular disease could interfere interpretation influence rituximab RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>T lymphocyte</keyword>
	<keyword>rituximab</keyword>
</DOC>